Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 OFFICER CERTIFICATION - SYNLOGIC, INC. | mirn_12312016x10kex321.htm |
| EX-31.2 - EXHIBIT 31.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER - SYNLOGIC, INC. | mirn_12312016x10kex312.htm |
| EX-31.1 - EXHIBIT 31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER - SYNLOGIC, INC. | mirn_12312016x10kex311.htm |
| EX-10.26(B) - EXHIBIT 10.26(B) O'NEILL EMPLOYMENT AGREEMENT - SYNLOGIC, INC. | exhibit1026boneillemployme.htm |
| EX-10..26(A) - EXHIBIT 10.26(A) O'NEILL OFFER LETTER - SYNLOGIC, INC. | exhibit1026aoneillofferlet.htm |
| EX-10.24(C) - EXHIBIT 10.24(C) IRVIN SEPARATION AGREEMENT - SYNLOGIC, INC. | exhibit1024cirvinseperatio.htm |
| 10-K - FORM 10-K - SYNLOGIC, INC. | mirn_12312016x10kdocument.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-207299 and 333-210466) pertaining to the 2008 Long Term Incentive Plan, 2015 Equity Incentive Plan and 2015 Employee Stock Purchase Plan of Mirna Therapeutics, Inc. of our report dated March 14, 2017, with respect to the financial statements of Mirna Therapeutics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2016, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Austin, Texas
March 14, 2017